Atwood & Palmer Inc. Has $21.83 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

Atwood & Palmer Inc. trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 1.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 353,345 shares of the medical equipment provider's stock after selling 4,390 shares during the quarter. Atwood & Palmer Inc. owned 0.16% of Hologic worth $21,826,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Geode Capital Management LLC boosted its stake in shares of Hologic by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider's stock valued at $412,159,000 after buying an additional 144,838 shares during the period. Victory Capital Management Inc. boosted its position in Hologic by 0.5% during the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider's stock worth $354,506,000 after purchasing an additional 24,358 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of Hologic by 3.0% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider's stock worth $322,272,000 after buying an additional 129,035 shares during the period. Invesco Ltd. lifted its position in shares of Hologic by 16.4% during the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock worth $293,434,000 after purchasing an additional 572,187 shares during the last quarter. Finally, Boston Partners boosted its position in shares of Hologic by 81.0% in the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock valued at $257,959,000 after acquiring an additional 1,602,463 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Stock Up 0.9%

HOLX stock traded up $0.57 during trading hours on Tuesday, reaching $65.14. 2,631,591 shares of the stock were exchanged, compared to its average volume of 2,297,103. The company has a market cap of $14.52 billion, a price-to-earnings ratio of 20.55, a PEG ratio of 2.14 and a beta of 0.55. The firm's 50-day moving average is $58.35 and its 200-day moving average is $65.16. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Hologic's revenue was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.03 earnings per share. On average, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Buying and Selling at Hologic

In other news, Director Martin D. Madaus purchased 5,445 shares of the company's stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the transaction, the director now owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.88% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on HOLX shares. Wall Street Zen cut Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Morgan Stanley reduced their target price on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Stephens dropped their target price on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research report on Tuesday, May 13th. Argus lowered shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Finally, Evercore ISI dropped their price objective on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a report on Friday, May 2nd. Twelve equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $77.42.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.